According to a release, health industry crowdfunding platform Poliwogg has announced a new partnership with the Epilepsy Foundation and Alpha 1 Foundation.
CEO and President of the Epilepsy Foundation Philip M. Gattone stated;
“Encouraging innovation is a central pillar of our mission. We are celebrating this partnership during the first anniversary of our merger with the Epilepsy Therapy Project. The partnership with Poliwogg leverages the strength of the merged organization’s combined resources to make an even bigger difference in the lives of all people living with seizures.”
Greg Simon CEO of Poliwogg commented on the partnership;
“Foundations have an enormously important role to play in identifying companies with promising approaches to improving the quality of life for people affected by debilitating and deadly diseases. The Epilepsy Foundation is a leader in bringing scientific and business diligence to bear in the interest of people with epilepsy. Poliwogg is proud to work with the Epilepsy Foundation as part of our mission to help fund promising companies by making health investments more accessible to millions of people.”
John Walsh, President and CEO of the Alpha-1 Foundation and a Board member of The Alpha-1 Project;
“Poliwogg is an ideal partner for the Alpha-1 Foundation and its venture philanthropy arm, The Alpha-1 Project. We must explore innovative ways to fund research in order to find the new therapies and ultimately the cures we need for lung and liver diseases caused by Alpha-1 Antitrypsin Deficiency.”
In a report on MedCityNews, New York’s Poliwogg will make these announcements today at the JP Morgan Healthcare Conference. The groups will leverage their networks to crowdfund some of the same innovations in for-profit, private crowdfunded investments. The foundations will get a first look at the deals, and companies funded through Poliwogg should expect investments between $1 million and $3 million. In some cases they could go as high as $10 million.
Poliwogg is a financial firm transforming healthcare investing. They provide pathways for accredited investors to invest in early stage companies in health and life sciences, structure indexes that quantify the impact of public companies in health, and are launching sector specific publicly registered venture funds focused by health vertical.